Perspective Therapeutics, Inc. logo CATX - Perspective Therapeutics, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 10
HOLD 2
SELL 0
STRONG
SELL 0
| PRICE TARGET: $11.50 DETAILS
HIGH: $12.00
LOW: $11.00
MEDIAN: $11.50
CONSENSUS: $11.50
UPSIDE: 270.97%

Stock News

Perspective Therapeutics: 'Strong Buy' On Bamzireotide Navoxetan Reinforced Data And Phase 3 Plans

Perspective Therapeutics: 'Strong Buy' On Bamzireotide Navoxetan Reinforced Data And Phase 3 Plans

Perspective Therapeutics remains a “Strong Buy,” driven by durable clinical data and multiple near-term catalysts across its radiopharmaceutical pipeline. The company's bamzireotide navoxetan for SSTR2-expressing NETs shows sustained efficacy and safety, with pivotal Phase 3 initiation targeted for late 2026. Upcoming data readouts for both NET and MC1R-positive melanoma programs, including ESMO 2026 and OPDIVO combination updates, present significant value inflection points.

Sep 01, 2026 02:23 PM • seekingalpha.com
Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2026 Financial Results

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2026 Financial Results

SEATTLE, July 31, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that it will report its second quarter 2026 financial results and provide a business update on Monday, August 10, 2026 after the market closes. The press release will be available on the newsroom section of the Company's website at https://perspectivetherapeutics.com/newsroom/press-releases.

Jul 31, 2026 02:30 AM • globenewswire.com
Ally Bridge Group NY LLC Makes New Investment in Perspective Therapeutics, Inc. $CATX

Ally Bridge Group NY LLC Makes New Investment in Perspective Therapeutics, Inc. $CATX

Ally Bridge Group NY LLC acquired a new position in Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 926,557 shares of the company's stock, valued at approximately $3,864,000. Perspective Therapeutics comprises 3.1% of Ally

Jul 28, 2026 11:45 PM • defenseworld.net
ADAR1 Capital Management LLC Purchases 654,142 Shares of Perspective Therapeutics, Inc. $CATX

ADAR1 Capital Management LLC Purchases 654,142 Shares of Perspective Therapeutics, Inc. $CATX

ADAR1 Capital Management LLC boosted its position in Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) by 687.2% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 749,335 shares of the company's stock after buying an additional 654,142 shares

Jul 28, 2026 11:45 PM • defenseworld.net
Perspective Therapeutics Receives European Orphan Medicinal Product Designation for [212Pb]VMT-α-NET in GEP-NETs

Perspective Therapeutics Receives European Orphan Medicinal Product Designation for [212Pb]VMT-α-NET in GEP-NETs

SEATTLE, July 28, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that the European Commission (EC) has granted orphan medicinal product designation for [²¹²Pb]VMT-α-NET for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The designation follows a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA).

Jul 28, 2026 02:30 AM • globenewswire.com
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Oral Presentation at the ESMO Congress 2026

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Oral Presentation at the ESMO Congress 2026

SEATTLE, July 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company's [212Pb]VMT-α-NET program have been accepted for presentation as detailed below at the European Society of Medical Oncology (ESMO) Congress 2026 taking place October 23 to 27, 2026 in Madrid, Spain. ESMO plans to release further details for regular abstracts on October 19, 2026.

Jul 17, 2026 08:22 AM • globenewswire.com
Perspective Therapeutics doses first brain tumor patient in expanded radiopharmaceutical trial

Perspective Therapeutics doses first brain tumor patient in expanded radiopharmaceutical trial

Perspective Therapeutics Inc. (NYSE-A:CATX) has treated the first patient with a type of brain tumor called meningioma using its experimental drug [212Pb]VMT-a-NET, broadening a clinical trial that previously focused only on a different cancer type known as neuroendocrine tumors. The new arm of the Phase 1/2a study, called LEMONaDE, aims to assess how safe the treatment is and whether it shows early signs of shrinking tumors in meningioma patients.

Jun 03, 2026 10:08 AM • proactiveinvestors.com
Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study

Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study

SEATTLE, June 03, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that the first meningioma patient was dosed with [212Pb]VMT-α-NET in the Company's ongoing Phase 1/2a study.

Jun 03, 2026 02:30 AM • globenewswire.com
Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma

Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma

SEATTLE, May 21, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updates on all three of its advancing clinical programs, [²¹²Pb]VMT-α-NET, [²¹²Pb]VMT01, and [²¹²Pb]PSV359, will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place from May 29 to June 2, 2026 in Chicago, IL.

May 21, 2026 01:51 PM • globenewswire.com
Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies

Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies

SEATTLE, May 18, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that the first patients were dosed with [212Pb]VMT-α-NET and [212Pb]PSV359 in two new cohorts of Phase 1/2a studies in neuroendocrine tumors and solid tumors, respectively.

May 18, 2026 02:30 AM • globenewswire.com
Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results

Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results

SEATTLE, May 11, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today provided a business update and announced results for the quarter ended March 31, 2026.

May 11, 2026 12:07 PM • globenewswire.com

Price Targets